At a glance
- Originator Abbott Laboratories
- Class Peptidomimetics
- Mechanism of Action Angiogenesis inhibitors; Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 24 Jan 2013 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 14 Oct 1999 New profile
- 14 Oct 1999 Preclinical development for Solid tumours in USA (Unknown route)